Price: $1.5200
$0.03
2.013%
|
Day's High:
| $1.53
| Week Perf:
| 10.14 %
|
Day's Low: |
$ 1.47 |
30 Day Perf: |
4.11 % |
Volume (M): |
211 |
52 Wk High: |
$ 3.36 |
Volume (M$): |
$ 321 |
52 Wk Avg: |
$2.31 |
Open: |
$1.47 |
52 Wk Low: |
$1.19 |
|
|
Market Capitalization (Millions $) |
253 |
Shares
Outstanding (Millions) |
167 |
Employees |
3,238 |
Revenues (TTM) (Millions $) |
1,960 |
Net Income (TTM) (Millions $) |
-55 |
Cash Flow (TTM) (Millions $) |
-6 |
Capital Exp. (TTM) (Millions $) |
5 |
111 Inc
111 Inc, also known as 111, is a leading digital healthcare platform company in China that aims to provide innovative, integrated solutions to customers and partners in the healthcare industry. The company was founded in Shanghai in 2010 and has since expanded to become one of the largest digital healthcare platforms in China.
111 operates several business segments that are designed to cater to the various needs of its customers. The company's main business segments are:
Pharmacy and healthcare services - this segment provides customers with online and offline healthcare services and prescription drug delivery services. The company operates a network of licensed drug stores and medical clinics that offer a range of healthcare services.
B2B pharmaceutical supply chain - this segment connects pharmaceutical manufacturers, distributors, hospitals and other healthcare providers through its digital platform, providing an integrated supply chain solution.
Insurance and healthcare management - a business segment that focuses on providing insurance companies with health management services and insurance products.
111's core services include providing pharmacy and healthcare services, a digital hospital platform and B2B pharmaceutical supply chain services. The company's digital hospital platform operates through its subsidiary DXY, which is a platform that connects patients, doctors and hospitals through its online and offline services. DXY is one of the largest online medical portals in China with over 20 million registered users.
In addition to its core services, 111 has also developed a range of innovative technology products that enhance its service offering. For example, the company's AI technology and big data analytics are used to improve patient experience and improve healthcare outcomes.
111 has a strong presence in China's major cities and has expanded to over 30 provinces and municipalities, covering over 90% of China's population. The company has also established strategic partnerships with leading pharmaceutical companies and healthcare providers in China.
111 Inc is listed on the NASDAQ exchange under the ticker symbol YI. The company has won several awards, including being recognized as an innovative company at the 2019 World Artificial Intelligence Conference.
Company Address: 3-5/F, No.295 ZuChongZhiRoad, Shanghai 201203
Company Phone Number: 21 2053-6666 Stock Exchange / Ticker: NASDAQ YI
YI is expected to report next financial results on April 27, 2024. |
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Hwh International Inc
The financial results for the fourth quarter of 2023 for HWH International Inc show a slight improvement in earnings per share compared to the previous year, but a decrease from the previous quarter. The revenue remained unchanged from both the previous year and the previous quarter. The company reported a net loss of $0.000 million for the quarter, which is a decrease from the corresponding quarter a year before. Looking at the fiscal year 2023 as a whole, HWH International Inc reported revenue of $0.00 million and earnings of $0.55 million. This indicates that the company was able to generate profits for the year despite experiencing a loss in the fourth quarter.
|
Petiq Inc
PETQ Reports Increased Loss Per Share for Recent Fiscal Period EAGLE, Idaho, Feb. 07, 2024 - PetIQ, Inc. (PetIQ or the Company) (Nasdaq: PETQ), a leading pet medication and wellness company, announced its financial results for the fourth quarter and full year ended December 31, 2023. Despite some unfavorable numbers, the company remains optimistic about its future performance. For the most recent fiscal period, PETQ reported a loss per share of $-0.60, compared to $-0.24 in the previous year. The Income per Share also fell from $0.02 to -$0.60 sequentially. However, there was a notable increase in revenue, which grew by 19.937% to $220.78 million from $184.08 million in the same quarter of the previous year.
|
Nu Skin Enterprises Inc
Nu Skin Enterprises Faces Significant Revenue and Profit Declines in Q4 2023 Nu Skin Enterprises Inc. (NYSE: NUS) recently released its fourth quarter and full-year 2023 financial results, which showed a significant decline in revenue and profits. In the fourth quarter of 2023, the company's revenue decreased by a staggering -6.518% to $488.30 million, compared to $498.27 million in the previous quarter. This decline in revenue directly impacted the company's profits, which plummeted by -87.26% to $0.15 per share, down from $1.16 per share in the corresponding quarter one year ago. The decline in revenue and profits is a cause for concern for Nu Skin Enterprises shareholders. The company's bottom-line also suffered, with a -87.27% decrease in net income from $57.215 million in the corresponding period a year before to $7.282 million in the fourth quarter of 2023. This significant decline in profits raises doubts about the company's ability to maintain its financial stability and sustainability.
|
Mckesson Corporation
McKesson Corporation, a leading healthcare services company, has experienced a significant increase in its stock performance in recent months. Over the past three months, the company's stock has improved by 15.42%. However, during the month of February, the stock dropped by 2.94%. Despite this dip, McKesson Corporation's stock has reached its 52-week high. One of the factors contributing to the fluctuation in McKesson Corporation's stock price is its financial performance. In the third quarter of the 2024 earnings season, the company experienced a decline in earnings per share (EPS) while revenue increased. EPS plummeted by -42.3% to $4.42 per share, while revenue showed an admirable increase of 14.765% to $80.90 billion compared to the same reporting season the previous year.
|
Cvs Health Corporation
CVS Health Corporation, a leading Pharmacy Services and Retail Drugstore company, experienced a slight decline in its shares during the month of February 2024. The shares dropped by -0.22%, bringing the year-to-date performance to -8.77%. Currently trading on the NYSE, CVS Health Corporation's shares are valued at 1% above its 52-week average. During the period from October to December 2023, CVS Health Corporation witnessed a reduction in its earnings per share (EPS) despite a significant increase in revenue. The profitability decreased by -9.26% to $1.59 per share, while the revenue grew extensively by 11.887% to $93.81 billion compared to the same period the previous year. This growth in revenue outpaced the top-line performance of most other companies in the Pharmacy Services and Retail Drugstore sector, as they reported an average revenue advance of 11.61% in the fourth quarter of 2023 compared to the previous year.
|
Per Share |
Current |
Earnings (TTM) |
-0.36 $ |
Revenues (TTM) |
11.76 $
|
Cash Flow (TTM) |
- |
Cash |
0.77 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.36 $
|
Revenues (TTM) |
11.76 $ |
Cash Flow (TTM) |
- |
Cash |
0.77 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
|